Related Experiment Video

Updated: Aug 14, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

[Respiratory syncytial virus]

Hiroyuki Tsutsumi1

  • 1Department of Pediatrics, Sapporo Medical University School of Medicine, Japan. tsutsumi@sapmed.ac.jp

Uirusu
|November 26, 2005
PubMed

Insights

Human respiratory syncytial virus (RSV) causes common infant infections. While vaccines failed, a new antibody significantly reduces hospitalizations in high-risk infants, offering improved prevention.

Area of Science:

  • Virology
  • Immunology
  • Pediatrics

Context:

  • Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRI) in infants.
  • Previous vaccination attempts for RSV prophylaxis were unsuccessful due to adverse effects.
  • Current RSV LRI management primarily relies on symptomatic treatment.

Purpose:

  • To review the current landscape of RSV prevention and treatment strategies.
  • To highlight the development and clinical introduction of a humanized anti-RSV F protein monoclonal antibody.
  • To discuss the ongoing investigation of novel anti-RSV drugs.

Summary:

  • RSV is a major global health concern for young infants.
  • An aerosolized antiviral, ribavirin, reduces viral load but not hospitalization duration or symptomatic needs.
  • A humanized anti-RSV F protein monoclonal antibody has shown significant success in reducing hospitalization rates in high-risk infants.

Impact:

  • The new monoclonal antibody offers a promising preventive measure for vulnerable infant populations.
  • This development marks a significant advancement in combating severe RSV infections.
  • Further research into novel anti-RSV drugs is crucial for future therapeutic options.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Coronavirus01:29

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...